Variations in Serum Sphingolipid Levels Associate With Liver Fibrosis Progression and Poor Treatment Outcome in Hepatitis C Virus but Not Hepatitis B Virus Infection
Variations in Serum Sphingolipid Levels Associate With Liver Fibrosis Progression and Poor Treatment Outcome in Hepatitis C Virus but Not Hepatitis B Virus Infection
复制标题
DOI：
10.1002/hep.27587
复制
发表时间：
2015-03-01
期刊：
影响因子：
13.5
通讯作者：
Pfeilschifter, Josef
中科院分区：
文献类型：
--
作者：
Grammatikos, Georgios;Ferreiros, Nerea;Pfeilschifter, Josef
极长链神经酰胺（Cers）消融与鞘氨酸水平的连续升高已被证明在敲除小鼠模型中引起严重的肝病。我们最近的研究表明，血清鞘脂（SLs）在慢性肝病患者中失调。然而，迄今为止，它们作为肝纤维化可能的生物标志物的作用仍未被探索。我们采用液相色谱/串联质谱法对406例慢性病毒性肝炎患者、203例基因1型丙型肝炎病毒（HCV）感染者和203例乙型肝炎病毒（HBV）感染者的血清各种SL代谢物浓度进行了评估。我们观察到血清SLs的显著变化，鞘氨醇和鞘氨氨酸都是单变量(P
Ablation of very-long-chain ceramides (Cers) with consecutive elevations in sphinganine levels has been shown to cause a severe hepatopathy in a knockout mouse model. We have recently shown that serum sphingolipids (SLs) are deregulated in patients with chronic liver disease. However, their role as possible biomarkers in liver fibrosis remains to date unexplored. We assessed, using liquid chromatography/tandem mass spectrometry, serum concentrations of various SL metabolites in 406 patients with chronic viral hepatitis, 203 infected with genotype 1 hepatitis C virus (HCV) and 203 with hepatitis B virus (HBV), respectively. We observed significant variations of serum SLs, with sphingosine and sphinganine being, both in univariate (P